Lanthanum carbonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Lanthanum carbonate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
73
Registered trials
30
Result records
20
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Lanthanum carbonate can convert its Small molecule drug profile and Phosphates biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Lanthanum carbonate (query alias: lanthanum carbonate) |
|---|---|
| Modality / target | Small molecule drug; Phosphates; Phosphates modulators |
| Highest global status | Approved |
| Originator | Sanofi |
| Active developers | Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Australia Pty Ltd., Takeda Pharmaceuticals U.S.A., Inc. |
The MCP disease footprint includes Hyperphosphatemia, Kidney Failure, Chronic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2019-003698-24-NL | Phase 4 | Not Recruiting | 40 | The main outcome is the difference over 22 weeks in patient satisfaction with phosphate treatment. The Treatment satisfaction Questionnaire for Medication (TSQM, version II) will be used to measure patient satisfaction. |
| NCT04440696 | Phase 1/2 | Unknown status | 48 | Blood phosphate concentrations |
| JPRN-jRCTs051180048 | Not Applicable | 研究終了 | 200 | rate of change in CACS |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: Serum phosphate = may slightly reduce serum phosphate mg/L ; Serum phosphate = may have little or no effect mg/L ; Serum phosphate = may have little or no effect mg/L
Effect of Lanthanum Carbonate on Serum Phosphate, Oxidative Stress, and Vascular Dysfunction in CKD
Phase 4; n=54; evaluation: Negative. Reported fields: Serum phosphate = 3.42 mg/dL ; Serum phosphate = 3.44 mg/dL
Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with Chronic Kidney Disease
Phase 2; n=127; evaluation: Positive. Reported fields: ADC = 1.46 x10-3 mm2/s ; ADC = 1.46 x10-3 mm2/s
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Lanthanum carbonate addresses Hyperphosphatemia, Kidney Failure, Chronic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 20 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Phosphates records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-12-31 | 宝龄富锦生技股份有限公司公告本公司與韓國協和醱酵麒麟及韓國樂金化學簽署轉換與轉讓協議 | Approved | Financial terms not disclosed |
| 2024-08-27 | 宝龄富锦生技股份有限公司接获新药Nephoxil韩国授权伙伴韩国协和麒麟公司终止授权与独家经销合约的通知 | Approved | Financial terms not disclosed |
| 2024-02-02 | 康哲药业获得一线降磷创新药“维福瑞®”独家许可权利 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Method for preparing, detecting and sorting lanthanum carbonate chewable tablets”. The milestone feed surfaced a patent-application signal described as “Preparation method of small-particle-size lanthanum carbonate tetrahydrate”. The milestone feed surfaced a patent-application signal described as “Method for preparing lanthanum carbonate tetrahydrate and product thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
